Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of intravenous single ascending doses of IM-250 in healthy volunteers
Latest Information Update: 09 Sep 2026
At a glance
- Drugs Adibelivir (Primary)
- Indications Herpes simplex encephalitis; Herpes simplex virus infections
- Focus Adverse reactions
- Sponsors Innovative Molecules
Most Recent Events
- 03 Jun 2026 Status changed from not yet recruiting to recruiting.
- 11 Dec 2025 New trial record